Conference detail

Teri Arri, tarri@smi-online.co.uk, +442078276000

Building on almost two decades worth of expertise in fighting the growing threat of antimicrobial resistance (AMR), SMi Group are thrilled to announce the return of Superbugs & Superdrugs USA which arrives to Iselin, New Jersey on NOV 13-14 2017.

Antimicrobial resistance has sparked an urgency in the development of new drugs as the industry strives for novel solutions to fight infectious diseases. Innovation and collaboration is requested at every level making Superbugs & Superdrugs USA, the perfect platform to strengthen knowledge in key principles such as funding incentives and global strategy, whilst honing in on clinical developments in areas such as immunotherapy, toxoid based vaccines and anti-body drug conjugates.

This is critical time for AMR experts, government bodies and industry leaders, to come together and share ideas on the latest developments in treatment and prevention.

Speakers Include:

Anthony Simon Lynch, Senior Scientific Dir, Janssen

William Weiss, Dir, Pre-Clinical Services, UNT Health Science Center

John Rex, CMO & Dir, F2G; Chief Strategy Officer, CARB-X

Christopher Houchens, Branch Chief, Antibacterials Program, BARDA

Annaliesa Anderson, VP & CSO Bacterial Vaccines, Pfizer

Olga Danilchanka, Microbiome Lead, Merck

Christopher McMaster, President & CEO, DemovaMed

Obadiah Plante, Dir of Research, Visterrra

Tim Opperman, Senior Research Scientist, Microbiotix

Ken Stover, Senior Dir, Infectious Diseases and Vaccines, MedImmune

Mike Westby, Dir, Centauri Therapeutics

Highlights:

Guidelines for successfully seeking funding and partnership with updates on the CARB-X initiative

Understand the importance of supporting natural immunity and the microbiome for reducing infection from resistant bacteria

New insight into treating gram-negative infections

Explore emerging and non-traditional approaches to antimicrobial drug development, including biologic drugs and combination treatment